P
Paolo Usai-Satta
Researcher at University of Pisa
Publications - 29
Citations - 1277
Paolo Usai-Satta is an academic researcher from University of Pisa. The author has contributed to research in topics: Irritable bowel syndrome & Internal medicine. The author has an hindex of 13, co-authored 25 publications receiving 1021 citations.
Papers
More filters
Journal ArticleDOI
Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.
Antonio Gasbarrini,Gino Roberto Corazza,G. Gasbarrini,Massimo Montalto,Di Stefano M,Guido Basilisco,Andrea Parodi,Paolo Usai-Satta,Piero Vernia,Caterina Anania,Marco Astegiano,Giovanni Barbara,Luigi Benini,Patrizia Bonazzi,Gabriele Capurso,M. Certo,Antonio Colecchia,Lucio Cuoco,Di Sario A,Davide Festi,C. Lauritano,Emanuela Miceli,Gerardo Nardone,Francesco Perri,Piero Portincasa,Risicato R,M. Sorge,Antonio Tursi +27 more
TL;DR: The final statements, graded according to the level of evidence and strength of recommendation, identify the indications for the use of H2-breath testing in the clinical practice and methods to be used for performing the tests.
Journal ArticleDOI
Loss-of-function of the Voltage-gated Sodium Channel NaV1.5 (Channelopathies) in Patients with Irritable Bowel Syndrome
Arthur Beyder,Amelia Mazzone,Peter R. Strege,David J. Tester,Yuri A. Saito,Cheryl E. Bernard,Felicity Enders,Weronica E. Ek,Peter T. Schmidt,Aldona Dlugosz,Greger Lindberg,Pontus Karling,Bodil Ohlsson,Maria Gazouli,Gerardo Nardone,Rosario Cuomo,Paolo Usai-Satta,Francesca Galeazzi,Matteo Neri,Piero Portincasa,Massimo Bellini,Giovanni Barbara,Michael Camilleri,G. Richard Locke,Nicholas J. Talley,Mauro D'Amato,Michael J. Ackerman,Gianrico Farrugia +27 more
TL;DR: Findings provide a new pathogenic mechanism for IBS and possible treatment options and suggest about 2% of patients with IBS carry mutations in SCN5A that disrupt NaV1.5 channel function.
Journal ArticleDOI
Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome.
Maria Henström,Lena Diekmann,Ferdinando Bonfiglio,Fatemeh Hadizadeh,Eva Maria Kuech,Maren von Köckritz-Blickwede,Louise B. Thingholm,Tenghao Zheng,Ghazaleh Assadi,C. Dierks,Martin Heine,Ute Philipp,Ottmar Distl,Mary E. Money,Meriem Belheouane,Femke-Anouska Heinsen,Joseph Rafter,Gerardo Nardone,Rosario Cuomo,Paolo Usai-Satta,Francesca Galeazzi,Matteo Neri,Susanna Walter,Magnus Simrén,Magnus Simrén,Pontus Karling,Bodil Ohlsson,Peter T. Schmidt,Greger Lindberg,Aldona Dlugosz,Lars Agréus,Anna Andreasson,Anna Andreasson,Emeran A. Mayer,John F. Baines,Lars Engstrand,Piero Portincasa,Massimo Bellini,Vincenzo Stanghellini,Giovanni Barbara,Lin Chang,Michael Camilleri,Andre Franke,Hassan Y. Naim,Mauro D'Amato,Mauro D'Amato +45 more
TL;DR: SI gene variants coding for disaccharidases with defective or reduced enzymatic activity predispose to IBS, and may help the identification of individuals at risk, and contribute to personalising treatment options in a subset of patients.
Journal ArticleDOI
Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy.
TL;DR: This review examines and discusses the pathophysiological aspects and the diagnostic and therapeutic approaches available for patients with symptoms possibly related to IBS, pointing out controversial issues and the strengths and weaknesses of the current knowledge.
Journal ArticleDOI
Lactose malabsorption and intolerance: What should be the best clinical management?
TL;DR: A therapeutic strategy consists of a lactose restricted diet avoiding the nutritional disadvantages of reduced calcium and vitamin intake, and there is insufficient evidence that these therapies are effective in lactose intolerance.